research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
Search
for
Sort by
Research
240-270 / 1000+ results 
research Alopecia Areata: Treatment Options and Efficacy
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research The Experts Meetings on Psoriasis: Recommendations for Daily Practice
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Retrospective Cohort Study of 90 Patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research An Excellent Response to Tofacitinib in a Brazilian Adolescent Patient with Alopecia Areata: A Case Report and Review of the Literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research One of the Best Treatments for Alopecia Areata Remains Unpublished
DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
research A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Case Report: Alopecia Areata Universalis Successfully Treated with Baricitinib
Baricitinib successfully treated severe hair loss.
research 63-Year-Old Female with Diffuse Thinning of the Hair
Androgenetic alopecia, a common hair loss condition, can be treated with topical minoxidil, oral finasteride, or oral spironolactone, and new treatments like platelet-rich plasma, low-level laser therapy, and janus-kinase inhibitors are being explored.
research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Balance of Tofacitinib Efficacy and Disease Flare in the Treatment of Alopecia Universalis: A Case Report and Review of the Literature
Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
research Topical Tofacitinib for the Treatment of Alopecia Areata Affecting Facial Hair
Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Upadacitinib for Management of Recalcitrant Alopecia Areata: A Retrospective Case Series
Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
research Upadacitinib for Management of Alopecia Areata and Rheumatoid Arthritis: Letter to the Editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Refractory Dermatomyositis–Systemic Lupus Erythematosus Overlap Syndrome and Response to Tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research Alopecia Areata in Children: An Overview of Clinical Features and Recent Treatment Options
New treatments for child hair loss due to immune issues are effective but not yet officially approved.
research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Janus Kinase Inhibitors Versus Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Annual Convention in the Time of COVID: The 2020 Dermatology Nurses' Association Meeting
The convention discussed various skin conditions and treatments, and highlighted the importance of vaccinations for patients on immune-altering medications.
research Updates From 2021 Virtual Dermatology Nurses' Association Convention
The convention discussed various skin conditions, treatments, and the importance of continuous learning in dermatology nursing.
research Are Janus Kinase (JAK) Inhibitors Beneficial in the Treatment of Androgenic Alopecia?
JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.
research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
research Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report
JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Screening for Latent Infectious Disease in Patients with Alopecia Areata Before Initiating JAK Inhibitors Therapy: A Single-Center Real-World Retrospective Study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
research Cytokine-Targeted Treatment in Alopecia Areata - New Possibilities?
New cytokine-targeted therapies show promise for treating alopecia areata.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.